POINT Biopharma Global Inc.

POINT Biopharma Global Inc. (NYSE: PNT) is a clinical-stage radiopharmaceutical company focused on the development and manufacturing of targeted radioligand therapies for oncology. The company came to public markets through a business combination with GX Acquisition Corp. II, a blank-check company sponsored by GX Sponsor II LLC that completed its IPO in 2020. POINT Biopharma operates in the life sciences and biopharmaceuticals sector, with an integrated manufacturing platform designed to support commercial-scale production of radiopharmaceutical drug candidates. The company filed a Form 10-Q with the SEC on November 2, 2020, under accession number 0001104659-20-120587. Sign up at SpacDesk for complete filing history, deal terms, and institutional analytics on PNT and hundreds of other SPAC transactions.